Journal of Orthopaedic Association of South Indian States,
Год журнала:
2023,
Номер
20(1), С. 55 - 59
Опубликована: Янв. 1, 2023
Viral
myalgia
in
post-COVID-19
has
been
a
common
presentation.
Musculoskeletal
affection
with
diffuse
viral
myositis
(VM)
an
uncommon
occurrence.
The
progression
of
to
avascular
necrosis
(AVN)
bilateral
femoral
heads
rarely
reported.
case
study
60-year-old
male
presented
painful
hips
difficulty
ambulation
simulating
pseudoparalysis.
magnetic
resonance
imaging
confirmed
along
both
the
which
needed
close
observation.
serial
at
3-month
intervals
showed
resolution
VM,
however,
AVN
heads.
unusual
was
initially
managed
medically,
later
it
necessitated
total
hip
replacement.
An
astute
clinician's
perspective
during
radiological
evaluation
allowed
identify
progression.
long
COVID-19
may
present
debilitating
musculoskeletal
around
VM
severe
acute
respiratory
syndrome
coronavirus
2
etiology
have
unrelenting
long-duration
affection.
A
multidisciplinary
team
approach
help
overcoming
crisis.
Rheumatology International,
Год журнала:
2023,
Номер
43(9), С. 1583 - 1595
Опубликована: Июнь 20, 2023
The
current
systematic
review
aimed
to
document
published
cases
of
femoral
head
avascular
necrosis
(FHAVN)
post-COVID-19,
report
the
COVID-19
disease
characteristics
and
management
patients
received,
evaluate
how
FHAVN
were
diagnosed
treated
among
various
reports.
A
literature
was
performed
per
Preferred
Reporting
Items
for
Systematic
Reviews
Meta-Analyses
(PRISMA)
guidelines
through
a
comprehensive
English
search
on
January
2023
four
databases
(Embase,
PubMed,
Cochrane
Library,
Scopus),
including
studies
reporting
post-COVID-19.
Fourteen
articles
included,
ten
(71.4%)
case
reports,
(28.6%)
series
reported
104
having
mean
age
42.2
±
11.7
(14:74)
years,
in
which
182
hip
joints
affected.
In
13
corticosteroids
used
during
plan
24.8
11
(7:42)
days,
with
prednisolone
equivalent
dose
1238.5
492.8
(100:3520)
mg.
142.1
107.6
(7:459)
days
passed
between
diagnosis
detection,
most
hips
stage
II
(70.1%),
concomitant
septic
arthritis
present
eight
(4.4%)
hips.
Most
(147,
80.8%)
non-surgically,
143
(78.6%)
received
medical
treatment,
while
35
(19.2%)
surgically
managed,
16
(8.8%)
core
decompression,
(7.1%)
primary
THA,
five
(2.7%)
staged
THA
three
(1.6%)
had
first
(debridement
application
antibiotic-loaded
cement
spacer).
outcomes
acceptable
as
regards
function
pain
relief.
Femoral
post-COVID-19
infection
is
real
concern,
primarily
attributed
corticosteroid
usage,
besides
other
factors.
Early
suspicion
detection
are
mandatory,
conservative
lines
effective
early
stages
outcomes.
However,
surgical
intervention
required
progressive
collapse
or
presented
late
stage.
Joint Diseases and Related Surgery,
Год журнала:
2022,
Номер
34(1), С. 75 - 83
Опубликована: Дек. 27, 2022
This
study
aims
to
evaluate
the
incidence
of
osteonecrosis
(ONC),
with
a
special
focus
on
ONC
femoral
head
(ONFH),
in
novel
coronavirus
disease
2019
(COVID-19)
patients
two
years
after
pandemic.This
prospective
included
COVID-19
who
were
admitted
our
center
between
March
2020
and
June
2020.
A
total
472
(289
males,
183
females;
mean
age:
42.3±12.0
years;
range,
18
60
years)
arranged
list
according
their
date
time
admission
and,
then,
divided
into
groups:
those
not
receiving
corticosteroid
(CS)
treatment
(Group
1,
n=236)
CS
2,
n=236).
The
evaluated
for
joint
pain
based
X-rays
magnetic
resonance
imaging
scans,
routinely
followed.
For
each
patient
Group
additional
data
regarding
use
recorded.
possible
relationship
risk
factors
was
analyzed.Both
groups
similar
terms
age
sex.
2
had
significantly
longer
hospitalization
period.
significant
increase
number
painful
joints
observed
2.
At
years,
5.1%
1
complained
at
least
one
compared
11.9%
Eight
from
developed
ONC.The
therapy
is
rise.
5%
various
doses
CSs
may
develop
ONC.
Residual
common
even
recovering
virus.
No
evident
duration
treatment,
cumulative
dosage
medication,
maximum
one-day
received,
presence
Diagnostics,
Год журнала:
2024,
Номер
14(3), С. 247 - 247
Опубликована: Янв. 24, 2024
Background:
The
COVID-19
pandemic
has
presented
numerous
challenges
to
the
global
healthcare
system
and
emerging
evidence
suggests
a
potential
link
between
treatment,
specifically
steroid
therapy,
development
of
avascular
necrosis
(AVN)
hip.
This
review
aims
provide
comprehensive
overview
recent
studies
case
reports
investigating
relationship
COVID-19,
corticosteroid
AVN.
Understanding
nuances
AVN
in
context
is
crucial
for
professionals
navigate
treatment
decisions
mitigate
complications.
Materials
Methods:
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analysis
(PRISMA)
were
used
systematic
until
1
September
2023.
full
texts
remaining
twenty-three
(n
=
23)
articles
independently
reviewed
by
authors
this
review.
Conclusions:
association
therapy
hip
noteworthy
concern
even
though
no
evident
duration
cumulative
dosage
medication,
maximum
daily
received,
presence
Further
research
with
larger
cohorts
long-term
follow
up
needed
better
understand
causative
optimal
management
strategies
therapy.
Anticoagulation
in
most
patients
with
familial
thrombophilia-hypofibrinolysis
and
primary
osteonecrosis
(ON)
before
hip
or
knee
collapse
relieves
pain,
prevents
joint
usually
averts
the
need
for
replacement
but
is
not
successful
secondary
ON
if
started
after
collapse.
Perthes
disease
acutely
appearing
post-COVID
patients,
particularly
when
factor
V
Leiden
present,
may
be
valuable
as
an
approach
to
prevent
otherwise
high
likelihood
of
subsequent
failure.
concurrent
should
considered
within
treatment
spectrum
ON.
International Journal of Community Medicine and Public Health,
Год журнала:
2025,
Номер
12(3), С. 1473 - 1478
Опубликована: Фев. 28, 2025
Avascular
necrosis
(AVN)
is
a
degenerative
bone
condition
characterized
by
the
death
of
tissue
due
to
reduced
blood
supply.
Recent
studies
suggest
an
increased
incidence
AVN
in
post-COVID-19.
This
may
be
linked
virus-induced
hypercoagulable
state
and
corticosteroid
treatment.
However,
there
dearth
evidence
substantiate
this
association.
Therefore,
case
series
aims
elucidate
potential
relationship
between
COVID-19
infection
AVN.
included
11
male
patients
(ages
25-49)
diagnosed
with
following
January
2022
August
2023.
The
results
indicated
higher
younger
males
(mean
age:
35
years,
range:
25-49),
highlighting
age-
gender-related
risks
among
Despite
excluding
pre-COVID
steroid
use,
occurred
those
exposure
during
treatment
even
home-isolated
cases
without
use.
Additionally,
study
reported
side
normal
range
D-dimer
CRP
levels,
suggesting
hypercoagulability
inflammation
have
accelerated
progression,
concurrent
alcohol
tobacco
use
potentially
increasing
risk.
Journal of Orthopaedic Surgery and Research,
Год журнала:
2025,
Номер
20(1)
Опубликована: Апрель 10, 2025
Abstract
Background
The
COVID-19
pandemic
has
claimed
many
lives
and
continues
to
impact
individuals
through
post-COVID-19
conditions.
Osteonecrosis
of
the
femoral
head
(ONFH)
is
increasingly
recognized
as
a
major
complication,
yet
most
studies
are
limited
case
reports
small
series.
This
study
aimed
evaluate
COVID-19-related
factors
potentially
contributing
ONFH
development
in
patients.
Methods
A
retrospective
analysis
was
conducted
on
84
patients
with
confirmed
history
COVID-19.
Baseline
characteristics
were
collected,
categorized
into
following
groups
for
comparative
analysis:
(1)
vaccinated
vs.
unvaccinated,
(2)
unilateral
bilateral
ONFH,
(3)
dexamethasone
(DEX)
methylprednisolone
(MPS)
DEX
therapy,
(4)
Association
Research
Circulation
Osseus
(ARCO)
stage
2
3.
Group
differences
associations
analyzed.
Results
MPS-treated
group
had
greater
extent
lung
involvement
compared
DEX-treated
(59.2%
36.3%,
p
=
0.002),
well
longer
hospital
stays
both
general
ward
(14.2
days
10.6
days,
0.018)
ICU
(5.4
3
0.017).
also
duration
steroid
therapy
(19.3
12.3
<
0.001)
received
higher
DEX-equivalent
cumulative
doses
(380
mg
125
mg,
0.001).
Notably,
symptoms
developed
earlier
(7.5
months
12
months,
0.004).
Multivariable
logistic
regression
identified
dose
sole
predictor
severity
(OR:
1.015,
95%
CI:
1.001–1.028,
0.032),
ARCO
receiving
than
(240
126
0.018).
Conclusions
Our
demonstrated
that
primary
determinant
Additionally,
combined
use
corticosteroids
may
accelerate
onset
highlighting
need
cautious
management
International Journal of Infectious Diseases,
Год журнала:
2022,
Номер
121, С. 11 - 13
Опубликована: Апрель 21, 2022
Recovery
from
COVID-19
is
not
always
uneventful,
especially
in
critically
ill
hospitalized
patients.
Persistent
symptoms
including
fatigue/
weakness,
shortness
of
breath,
anxiety,
and
depression
have
been
described
at
one-year
follow-up.
Furthermore,
the
musculoskeletal
system
like
joint
pain
or
stiffness
are
underreported
studies
with
long-term
follow-up
up
to
one
year.
Infection
SARS-CoV-2
itself
has
associated
endothelial
damage,
together
high-dose
corticosteroid
treatment,
it
predisposed
dissemination
microthrombi
development
femoral
head
osteonecrosis
(FHOn),
as
shown
during
previous
(2003–2004)
coronavirus
outbreaks.
A
resurgence
FHOn
cases
anticipated
but
this
reflected
existing
Prompt
diagnosis
critical
for
early
treatment
possibly
hip
preservation.
Patients
treated
corticosteroids
should
be
screened
avascular
necrosis
after
discharge
hospital.
Every
healthcare
worker
involved
management
these
patients
maintain
a
high
level
suspicion
alert
when
report
such
vague
aches
buttocks,
area,
adductors,
and/or
above
knee.
Studies
needed
identify
risk
factors
disease
severity,
type
steroid,
cumulative
dose,
duration
treatment.
